Image Source: AsiaOne
Relay Medical and Glow LifeTech Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based On Its MyCell Technology™GlobeNewswireJanuary 14, 2021Glow LifeTech has the exclusive rights for MyCell Technology™ in the United States, Canada and Mexico for one of the primary ingredients used in ArtemiC™, a COVID-19 Treatment Candidate with successful Phase II Clinical ResultsThe formulation statistically significantly improved the clinical recovery of COVID-19 patients in the treatment group in comparison with placebo and 100% of the patients in the treatment group fully recovered within 15 daysPositive results from a phase II double blind randomized controlled clinical trial show the MyCell Technology™ ArtemiC™ formulation, successfully met the primary and secondary endpoints for safety and efficacy1ArtemiC™ is a natural anti-inflammatory formulation by Glow partne
Source: AsiaOne